Celon Pharma (WAR:CLN) Cyclically Adjusted Book per Share: zł12.57 (As of Mar. 2026)


WAR:CLN Celon Pharma SA WAR:CLN
48 GF Score
Price zł19.78
GF Value zł23.01
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Cyclically Adjusted Book per Share?

Celon Pharma WAR:CLN -0.10% 48 Cyclically Adjusted Book per Share is zł12.57 as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 48/100 and a GF Value™ of zł23.01 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Celon Pharma's adjusted book value per share for the three months ended in Mar. 2026 was zł9.818. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is zł12.57 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-05), Celon Pharma's current stock price is zł19.78. Celon Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was zł12.57. Celon Pharma's Cyclically Adjusted PB Ratio of today is 1.57.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Celon Pharma was 1.91. The lowest was 1.55. And the median was 1.72.


Celon Pharma  (WAR:CLN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Celon Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=19.78/12.57
=1.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Celon Pharma was 1.91. The lowest was 1.55. And the median was 1.72.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Celon Pharma Cyclically Adjusted Book per Share Related Terms


Celon Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Cyclically Adjusted Book per Share Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 12.27

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 12.16 12.27 12.57

WAR:CLN vs ZTS, UTHR, VTRS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Cyclically Adjusted PB Ratio falls into.


WAR:CLN
48GF Score
Celon Pharma SA WAR:CLN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celon Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=9.818/163.0700*163.0700
=9.818

Current CPI (Mar. 2026) = 163.0700.

Celon Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 99.552 0.000
201609 0.000 99.064 0.000
201612 8.944 100.366 14.532
201703 9.057 101.018 14.620
201706 9.303 101.180 14.993
201709 9.435 101.343 15.182
201712 9.774 102.564 15.540
201803 9.942 102.564 15.807
201806 9.954 103.378 15.702
201809 10.071 103.378 15.886
201812 9.972 103.785 15.668
201903 10.116 104.274 15.820
201906 9.828 105.983 15.122
201909 9.887 105.983 15.213
201912 9.890 107.123 15.055
202003 9.456 109.076 14.137
202006 9.838 109.402 14.664
202009 9.863 109.320 14.712
202012 7.656 109.565 11.395
202103 8.250 112.658 11.942
202106 8.141 113.960 11.649
202109 12.468 115.588 17.590
202112 11.869 119.088 16.252
202203 10.410 125.031 13.577
202206 9.863 131.705 12.212
202209 9.629 135.531 11.586
202212 9.398 139.113 11.016
202303 9.175 145.950 10.251
202306 9.136 147.009 10.134
202309 9.010 146.113 10.056
202312 8.727 147.741 9.632
202403 8.402 149.044 9.193
202406 8.997 150.997 9.716
202409 9.585 153.439 10.187
202412 8.266 154.660 8.715
202503 7.790 157.021 8.090
202506 7.151 157.509 7.403
202509 7.226 158.000 7.458
202512 6.745 158.320 6.947
202603 9.818 163.070 9.818

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of zł12.57 mean?
Celon Pharma (WAR:CLN) has a Cyclically Adjusted Book per Share of zł12.57 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Cyclically Adjusted Book per Share too high?
Celon Pharma's current Cyclically Adjusted Book per Share is zł12.57. Overall, Celon Pharma has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Celon Pharma's Cyclically Adjusted Book per Share of zł12.57 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Celon Pharma and its competitors. Celon Pharma's current Cyclically Adjusted Book per Share is zł12.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.01, compared to a current price of zł19.78 — trading 14% below its estimated fair value. The current Cyclically Adjusted Book per Share is zł12.57. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Cyclically Adjusted Book per Share is zł12.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.78 is trading 14% below its estimated GF Value™ of zł23.01. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Cyclically Adjusted Book per Share: zł12.57
  • GF Value™: zł23.01 vs. price of zł19.78 (14% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for WAR:CLN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.78
Price
zł23.01
GF Value